Freund's vaccine adjuvant promotes Her2/Neu breast cancer

被引：0
作者：
Michelle S Cotroneo
Jill D Haag
Nicholas R Stapel
Jordy L Waller
Stephan Woditschka
Michael N Gould
机构：
[1] University of Wisconsin-Madison,McArdle Laboratory for Cancer Research, Department of Oncology
来源：
BMC Cancer | / 9卷
关键词：
Breast Cancer; Mammary Gland; Breast Cancer Risk; Mammary Carcinoma; Serum Haptoglobin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Influences of apolipoprotein E polymorphism on the risk for breast cancer and HER2/neu status in Taiwan
    Nai-Wen Chang
    Dar-Ren Chen
    Chen-Ten Wu
    Bradley E. Aouizerat
    Fei-Na Chen
    Shin-Jer Hung
    Shiuan-Huei Wang
    Ming-Feng Wei
    Cheng-Shyong Chang
    Breast Cancer Research and Treatment, 2005, 90 : 257 - 261
  • [42] Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer
    Susanne Taucher
    Margaretha Rudas
    Robert M. Mader
    Michael Gnant
    Emanuel Sporn
    Peter Dubsky
    Sebastian Roka
    Thomas Bachleitner
    Florian Fitzal
    Daniela Kandioler
    Catharina Wenzel
    Günther G. Steger
    Martina Mittlböck
    Raimund Jakesz
    Breast Cancer Research and Treatment, 2003, 82 : 207 - 213
  • [43] Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer
    Schoenherr, Regine M.
    Kelly-Spratt, Karen S.
    Lin, ChenWei
    Whiteaker, Jeffrey R.
    Liu, Tao
    Holzman, Ted
    Coleman, Ilsa
    Feng, Li-Chia
    Lorentzen, Travis D.
    Krasnoselsky, Alexei L.
    Wang, Pei
    Liu, Yan
    Gurley, Kay E.
    Amon, Lynn M.
    Schepmoes, Athena A.
    Moore, Ronald J.
    Camp, David G., II
    Chodosh, Lewis A.
    Smith, Richard D.
    Nelson, Peter S.
    McIntosh, Martin W.
    Kemp, Christopher J.
    Paulovich, Amanda G.
    PROTEOMICS CLINICAL APPLICATIONS, 2011, 5 (3-4) : 179 - 188
  • [44] Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer
    Taucher, S
    Rudas, M
    Mader, RM
    Gnant, M
    Sporn, E
    Dubsky, P
    Roka, S
    Bachleitner, T
    Fitzal, F
    Kandioler, D
    Wenzel, C
    Steger, GG
    Mittlböck, M
    Jakesz, R
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 (03) : 207 - 213
  • [45] Influences of apolipoprotein E polymorphism on the risk for breast cancer and HER2/neu status in Taiwan
    Chang, NW
    Chen, DR
    Wu, CT
    Aouizerat, BE
    Chen, FN
    Hung, SJ
    Wang, SH
    Wei, MF
    Chang, CS
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 90 (03) : 257 - 261
  • [46] Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu
    Fry, Elizabeth A.
    Taneja, Pankaj
    Inoue, Kazushi
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (03) : 495 - 503
  • [47] The effect of neoadjuvant chemotherapy on hormone receptor status, HER2/neu and prolactin in breast cancer
    Pedrini, Jose Luiz
    Savaris, Ricardo Francalacci
    Schorr, Mario Casales
    Cambruzi, Eduardo
    Grudzinski, Melina
    Zettler, Claudio Galleano
    TUMORI JOURNAL, 2011, 97 (06): : 704 - 710
  • [48] Elevated HER2 Extracellular Domain Level in Primary Breast Cancer with HER2 Overexpression Predicts Early Failure of Adjuvant Trastuzumab
    Thureau, Sebastien
    Clatot, Florian
    Laberge-Le-Couteulx, Sophie
    Baron, Marc
    Basuyau, Jean-Pierre
    Blot, Emmanuel
    ANTICANCER RESEARCH, 2012, 32 (04) : 1429 - 1433
  • [49] Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer
    Lauterlein, Jens-Jacob L.
    Petersen, Eva R. B.
    Olsen, Dorte Aa
    Ostergaard, Birthe
    Brandslund, Ivan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (05) : 877 - 883
  • [50] Predictive value of HER2 expression for the selection of adjuvant chemotherapy in breast cancer patients
    Hegmane, A.
    Vikmanis, U.
    BREAST CANCER RESEARCH, 2007, 9 (01)
12345